What Did This CEO Just Do with Personal Shares of Retrophin (RTRX)?


Yesterday, the CEO of Retrophin (RTRX), Steve Aselage, sold shares of RTRX for $240.

See today’s analyst top recommended stocks >>

Based on Retrophin’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $40.71 million and GAAP net loss of $54.52 million. In comparison, last year the company earned revenue of $40.34 million and had a GAAP net loss of $17.79 million. Currently, Retrophin has an average volume of 432.8K.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Retrophin, Inc. is a biopharmaceutical company, which engages in identifying, developing, and delivering therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts